Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2020-04-16 Regulatory Filings
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
EVOTEC ENTERS NANOMEDICINE THROUGH STRATEGIC PARTNERSHIP WITH LEON-NANODRUGS
Regulatory Filings Classification · 100% confidence The document is a press release dated April 16, 2020, announcing a strategic partnership and equity investment between Evotec SE and leon-nanodrugs GmbH. It details a business development, collaboration terms, and an investment in a private company's Series B funding round. This type of announcement, which details corporate strategy, partnerships, and financing activities (specifically an equity investment leading a funding round), fits best under the Capital/Financing Update category, as it involves a change in capital structure/investment strategy, although it is primarily a business development announcement. Since there is no specific code for 'Strategic Partnership/M&A Announcement' (TAR is for M&A/Takeover bids, which this is not), and it involves a significant equity investment, 'CAP' (Capital/Financing Update) is the most appropriate fit among the provided options, as it covers fundraising and capital structure changes. It is not an Earnings Release (ER), Interim Report (IR), or a formal regulatory filing like a 10-K.
2020-04-16 English
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in voting rights percentages and the nature of the instruments causing the change (e.g., acquisition/disposal of shares or instruments). It references specific German securities law (WpHG) and details the shareholder (Morgan Stanley) crossing a threshold. This directly matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA), although the primary focus here is the notification of a change in holding, which is also closely related to Major Shareholding Notification (MRQ). However, the header 'Voting Rights Announcements' and the structure strongly suggest DVA, which covers voting rights changes, or MRQ, which covers major shareholding changes. Since the document explicitly reports the crossing of a voting rights threshold and is titled as such, DVA is the most precise fit among the provided options, as MRQ is defined as 'Notification of changes in significant share ownership levels (crossing thresholds)', which is essentially what a voting rights announcement does when thresholds are crossed. Given the explicit mention of 'Voting Rights Announcements' in the header, DVA is selected.
2020-04-14 English
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 100% confidence The document is explicitly titled 'Notification of Major Holdings' and details changes in voting rights percentages held by Allianz Global Investors GmbH in Evotec SE, crossing a threshold on April 3, 2020. This type of filing, concerning changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification. The filing code for this is MRQ.
2020-04-06 English
EVOTEC AND TAKEDA ENTER INTO MULTI-YEAR GENE THERAPY RESEARCH ALLIANCE
M&A Activity Classification · 99% confidence The document is a press release dated April 6, 2020, announcing a 'MULTI-YEAR GENE THERAPY RESEARCH ALLIANCE' between Evotec SE and Takeda. It details a strategic partnership for drug discovery programs. This type of announcement, which details a significant business development, partnership, or strategic agreement without being a formal financial report (like 10-K or IR) or a specific transaction report (like DIRS or POS), typically falls under general corporate news or regulatory filings. Since it is a specific announcement about a business alliance and not a standard financial report, it is best classified as a general Regulatory Filing (RNS) as it is disseminated via DGAP (a service for regulatory announcements) and does not fit the more specific categories like M&A (TAR) or Capital Change (CAP). It is not an Earnings Release (ER) or a Call Transcript (CT).
2020-04-06 English
EVOTEC EXPANDS INTO GENE THERAPY
Environmental & Social Information Classification · 99% confidence The document is a press release dated April 6, 2020, announcing a strategic business development: Evotec is expanding into gene therapy by establishing a new R&D site. It uses keywords like 'News Details', 'DGAP-News', and discusses strategic direction and market outlook, but it is not a formal periodic financial report (like 10-K or IR), an earnings release (ER), or a transcript (CT). It is a general corporate announcement regarding business operations and strategy. Since it is a news release about a significant corporate development that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate classification is the general regulatory announcement/news category, RNS, as it is disseminated via DGAP (a service for regulatory announcements and news). It is too detailed and strategic to be a simple Report Publication Announcement (RPA).
2020-04-06 English
EVOTEC EXPANDS ITS IPSC-BASED CELL THERAPY PLATFORM EVOCELLS THROUGH LICENSING AGREEMENT WITH PANCELLA
M&A Activity Classification · 99% confidence The document is a press release dated April 2, 2020, announcing a licensing and investment agreement between Evotec SE and panCELLa Inc. regarding cell therapy technologies. It details a business development event (licensing and investment) rather than reporting periodic financial results (like 10-K or IR), announcing management changes (MANG), or detailing insider trades (DIRS). It is a corporate news announcement concerning strategic partnership and technology acquisition. Since it is a general corporate announcement that doesn't fit the specific categories like M&A (TAR) or Capital Change (CAP), and it is not a transcript (CT) or a formal regulatory filing like a 10-K, the most appropriate classification is the general regulatory/corporate announcement category, RNS, as it is disseminated via DGAP (a service often used for regulatory news). However, given the content is a strategic business development announcement, it is often categorized under 'Regulatory Filings' (RNS) when a more specific business event code is unavailable. Since the content is a detailed announcement of a strategic agreement, it is not a short 'Report Publication Announcement' (RPA). RNS serves as the best fit for significant, non-periodic corporate news.
2020-04-02 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.